Chugai Pharmaceutical Co., Ltd. takes great care over the information presented on this website, but it does not guarantee its accuracy, completeness, usefulness, etc. for Total Access. Chugai Pharmaceutical Co., Ltd. manufactures and sells pharmaceuticals products. Chugai Pharmaceutical Co,. Chugai Pharmaceutical Co., Ltd. takes great care over the information presented on this website, but it does not guarantee its accuracy, completeness, usefulness, etc. | Chugai Pharma Europe is the European hub of the Chugai Group, and has been bringing novel therapies to patients since 1993. The company develops drugs in the fields of cancer, infectious diseases, bone, blood, and circulatory systems. Add Hours More Info Neighborhoods Midtown Manhattan, Midtown East AKA Chugai Pharma USA LLC Chugai Pharmaceutical is a pharmaceutical company specializing in the fields of oncology, as well as bone, joint, and renal diseases. Interviewed prescribers to understand their expectations and built a sales forecast model Chugai Pharmaceutical Co., Ltd. (Chugai) was founded in Japan in 1925. Oncology) Home Investor Relations Chugai Pharma USA 440 Madison Ave Ste 1201, New York, NY 10022 - YP.com Home NY New York Pharmaceutical Products Manufacturers Chugai Pharma USA Claim this Business Chugai Pharma USA Pharmaceutical Products-Wholesale & Manufacturers Be the first to review! Recent Locations. Chugai reported financial results for 2021 (Core-basis) with revenues of 999.8 billion (+212.9 billion, +27.1%). - Full P&L accountability/annual financial statements, sales of 550 Mio. 300 Connell Dr Ste 3100. Research and Development. Disclosure of Information According to the "Guidelines for Cooperation Between Chugai and Patient Groups". Products under Development by Stage of Development Products under Development by Therapy Area . Furthermore, Chugai Pharma . For further details, please read the following "Terms and Conditions of Website Use.". Tokyo. Ltd. ("Pharmabody" is coined from the words pharmaceutical and antibody.) 2. Our work here at CPUSA focuses on the early stages of the drug development process, from both a clinical and regulatory perspective. Chugai Pharma Europe Logistics is responsible for the supply of some of Chugai's products in Europe. RT @WSjp_insight: http://ws-jp.co.jp/2020/11/14/science-technology-14-coronavirus-15-pharmaceutical-products-6/Tocilizumab/Atlizumab(Actemra) #coronavirus . Aloxi (palonosetron) Soft Capsules Aloxi (palonosetron) Solution for Injection Granocyte (lenograstim) Powder and Solvent for Solution for Injection/Infusion RoActemra (tocilizumab) Solution for Injection in Pre-Filled Pen RoActemra (tocilizumab) Solution for Injection in Pre-Filled Syringe Chugai Pharmaceutical Co., Ltd., specializing in prescription pharmaceuticals and based in Tokyo, is one of Japan's leading research-based pharmaceutical companies with strengths in biotechnology products. See reviews, photos, directions, phone numbers and more for Chugai Pharma Usa locations in Teaneck, NJ. Chugai is a leading research-based pharmaceutical company with strengths in biotechnology products, and brings to the collaboration substantial expertise and experience in late-stage development . The foundation of CPUSA is rooted in our parent company Chugai Pharmaceutical's rich heritage of pipeline and products across therapeutic areas, including many unique and innovative compounds. Headquartered in London, we employ over 250 highly-skilled experts, with offices in the UK, Germany and France. Schedule A Demo. Chugai Pharma France is a simplified joint-stock company (SAS) with approximately 90 employees. Some of Chugais global development achievements that exemplify first-in-class/best-in-class include: CPUSA completed early stage development of Alecensa (alectinib) and GC33 in the U.S. before out-licensing to Roche. Chugai Pharma USA, Inc. (CPUSA), located in Berkeley Heights, NJ, is a wholly owned subsidiary of Chugai Pharmaceutical Co., Ltd. (Chugai). 300 Connell Dr Ste 3100. CPUSA currently has several ongoing development programs, where Chugai is independently pursuing global development of its original products; future studies for other drug candidates are currently in planning. Chugai Pharma USA, Inc. 300 Connell Drive, Suite 3100 Berkeley Heights, NJ 07922, U.S.A. +1-908-516-1350 Activities: Clinical development and regulatory affairs for pharmaceutical products in the U.S. Chugai Pharma China Co., Ltd. Building G31, No. Disclosure of Information According to the "Guidelines for Cooperation Between Chugai and Patient Groups", Information on Chugai Groups Response to the Novel Coronavirus, Beware of Solicitations, Phishing e-mails, and SNS that Fraudulently Use the Name of Chugai Pharmaceutical. Mission Statement and Chugai Group Code of Conduct, History of Chugai Pharmaceutical / Nippon Roche (chronology), Strengthen the digital platform/Optimize all value chains, Auditing System and Internal Control System, Policy regarding the strategic shareholdings, Corporate Governance report and related materials, See how Chugai compares to other companies, Context of Our Efforts to Create Shared Value, Initiatives for Sustainable Patient-Centric Healthcare, Patient-Centric Activities to HelpResolveSocial Issues in theField ofRare Disease, Human Resources and Diversity & Inclusion, Initiatives to Promote the Success of Diverse Employees, Healthcare Compliance based on the Chugai Code of Practice, Policy on Research Using Human Stem Cells, Measure, Purchasing Policy and Chugai Ethical Purchasing Standards, Creation of a System for Comprehensive Assessment of Suppliers, Education regarding respect for human rights, Environmental, Health and Safety Policy/Basic Approach, Disclosures based on the TCFD recommendations, Introduction of eco-friendly product packaging materials, Promoting Health and Productivity Management, Guidelines on Relation with Medical Institutions and Patient Groups. ", first-in-class IL-6 signal blockade agent for rheumatoid arthritis and other autoimmune diseases, new generation ALK inhibitor for non-small cell lung cancer, with Breakthrough Therapy designation by the FDA, anti-glypican 3 monoclonal antibody for hepatocellular carcinoma under co-development with Roche, anti-factor IXa/X bispecific antibody, novel concept treatment for hemophilia A (co-development with Roche) with Breakthrough Therapy designation by the FDA. May 14, 2015 Warning against Phishing e-mails and social networking sites using the name of Chugai Pharmaceutical. We will continue pursuing innovation in order to provide better value to patients," said Dr. Osamu Okuda, Chugai's President and CEO. Specifically, Chugai is working to develop innovative products which may satisfy the unmet medical needs in Chugais strategic fields of oncology, bone and joint diseases, and renal diseases as well as other therapeutic areas with serious unmet needs. Jun 2017 - Dec 20192 years 7 months. Please contact Roche drug safety centre by emailing Roche. Innovative Medicines Business Unit, reporting to the Business Unit Director, Bristol-Myers Squibb (BMS) UK & Ireland. CLOSED NOW. Support Center Find answers to questions about products, access, use, setup, and administration. The primary focus of all Chugai Pharmaceutical's activities is to serve patients by developing products that address unmet medical needs and improve lives. Oncology) Oncology Area Specialty Area (excl. Chugais strength in R&D and antibody technologies continues on in global efforts for products and services for the benefit of patients. importation, and exportation of pharmaceuticals in Japan and internationally. With a pioneering spirit, Chugai Pharmaceutical Co., Ltd., headquartered in Tokyo is a research-based pharmaceutical company with world-class drug discovery capabilities, including proprietary antibody engineering technologies. Chugai, based in Tokyo, specializes in prescription pharmaceuticals and is listed on the 1st section of the Tokyo Stock Exchange. Chugai Pharmaceutical founded in 1925, is one of Japan's leading research-based pharmaceutical companies with strengths in biotechnology products. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla . Chugai has a 30-year history in biopharmaceuticals, focused on the creation of first and best-in-class products. About CGTP 2021. Berkeley Heights, NJ 07922. Uxbridge, Greater London, United Kingdom. Where? Chugai Pharma Europe Ltd takes great care over the information presented on this website, but it does not guarantee its accuracy, completeness, usefulness, etc. Adverse events for Hemlibra , RoActemra and Alecensa should be reported to Roche Products Ltd. . Taiyo Holdings, Taiyo Pharma, and Chugai will cooperate closely to achieve a smooth transfer of marketing authorization and marketing activities regarding the Products. View the status of our current development pipeline as of Jul 21, 2022 in a PDF format. See reviews, photos, directions, phone numbers and more for Chugai Pharma Usa locations in Parsippany, NJ. Payments to Medical Institutions, Healthcare Professionals, etc. Post di Chugai Pharma Europe Chugai Pharma Europe 3.905 follower 1 settimana Modificato Segnala post Are you attending BIO-Europe 2022? Chugai always pursue medical superb with patient-centric principle. YEARS IN BUSINESS (908) 516-1350. Furthermore, Chugai Pharmaceutical Co., Ltd. will not be responsible for any damages resulting from the use of this website or the information presented on this website. Chugai Pharmabody Research Pte. 1. The Company develops drugs in the fields of cancer, infectious diseases, bone, blood, and circulatory systems.. What are you looking for? Pharmaceutical Products-Wholesale & Manufacturers. Find. Chugai is one of Japans leading research-based pharmaceutical companies with strengths in biotechnology products. Pharmaceutical Products-Wholesale & Manufacturers. . For further details, please read the following "Terms and Conditions of Website Use. Copyright Chugai Pharmaceutical Co., Ltd. All rights reserved. Dedicated to adding value by creating and delivering innovative products and services for the medical community . Ltd. was established in 1925. . Address 1-8-2 Kyutaromachi Chuo-ku City, State / Prefecture, Postal Osaka-shi , 541-8564 ", Chugai Pharma USA, LLC is now Chugai Pharma USA, Inc, Aug 11, 2015 Caution Regarding False Solicitations on Behalf of Chugai, May 14, 2015 Warning against Phishing e-mails and social networking sites using the name of Chugai Pharmaceutical, Chugai Announces 2022 3rd Quarter Results, F. Hoffmann-La Roche Announces Third Quarter Sales 2022, Construction of Chugais New Research Center Chugai Life Science Park Yokohama Reached Completion. Chugai is one of Japan's leading research-based pharmaceutical companies with strengths in biotechnology products. As of October 15th, there was short interest totalling 115,900 shares, an . Payments to Medical Institutions, Healthcare Professionals, etc. Chugai Pharma USA, Inc. takes great care over the information presented on this website, but it does not guarantee its accuracy, completeness, usefulness, etc. The CASSS Cell and Gene Therapy Products symposium enables the exchange of scientific ideas and dialogue with regulators that form the basis of evolving regulatory practices in the development of these diverse and innovative products. Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. Research Chugai Pharmaceutical (4519 N) stock with daily updated analysis. The property is bordering the west side of Chugai's Ukima Site. Chugai Main Products PDF [PDF 499KB] Oncology Area Specialty Area (excl. Berkeley Heights, NJ 07922. Furthermore, Chugai Pharmaceutical Co., Ltd. will not be responsible for any damages resulting from the use of this website or the information presented on this website. Inscrivez-vous pour entrer en relation Chugai Pharma Europe . My Research and Language Selection Sign into My Research Create My Research Account English; Help and support. As an important member of the Roche Group, Chugai is actively . What are you looking for? Establishment January 10, 2012 Location 3 Biopolis Drive, #07-11 to 16 Synapse, Singapore 138623 Commencement of Operations July 2, 2012 Capital S$ 1.5 million CEO Hideaki Shimada Ph.D. Access the link. Chugai, based in Tokyo, specializes in prescription pharmaceuticals and is listed on the 1st section of the Tokyo Stock Exchange. Chugai Pharma Europe Ltd. is the European HQ of Chugai - with Group companies in France, Germany, and the UK. Chugai Pharma Germany GmbH, based in Frankfurt / Main, is the German affiliate of Chugai Pharma Europe. Margaux Jegou and our partnering team are looking forward to joining in October to discuss how we could work with you to achieve more for patients, together. CPUSA supports the planning and execution of global and U.S. clinical programs for Chugai originated innovative new drug candidates. Chugai has been a member of the Roche Group since 2002. oncology).View details in a PDF format. Chugai Pharmaceutical Co., Ltd. takes great care over the information presented on this website, but it does not guarantee its accuracy, completeness, usefulness, etc. For more information about our parent company, please visit Chugai Pharmaceutical Co., Ltd. Chugai Pharma USA, Inc. takes great care over the information presented on this website, but it does not guarantee its accuracy, completeness, usefulness, etc. Furthermore, Chugai Pharmaceutical Co., Ltd. will not be responsible for any damages resulting from the use of this website or the information presented on this website. . GET STARTED. Chugai Pharmaceutical manufactures and sells pharmaceuticals products. Managing Director with shared overall accountability for Medac s entire operations and 1840 employees. Show only: Furthermore, Chugai Pharma USA, Inc. will not be responsible for any damages resulting from the use of this website or the information presented on this website. In Germany we believe that "The Power of Together" empowers us to alleviate disease and improve the quality of life of patients. Chugai Pharma Europe Ltd takes great care over the information presented on this website, but it does not guarantee its accuracy, completeness, usefulness, etc. EU regulatory strategy lead for numerous products in early development in oncology and other disease areas including monoclonal antibodies (mAbs) and providing regulatory advice and support to . Furthermore, Chugai Pharmaceutical Co., Ltd. will not be responsible for any damages resulting from the use of this website or the information presented on this website. Aug 22, 2022 CEO Message Movie "Our Vision of Chugai Group as a Top Innovator in 2030" Jul 21, 2022 Financial Results for Second Quarter of Fiscal Year 2022 (Jan-Jun 2022) About Chugai Chugai's Five Strengths Message from the CEO R&D Clinical Development Strategic Alliance with Roche Chugai's Response to the Novel Coronavirus Table 30: Pipeline by Chugai Pharmaceutical Co Ltd, 2022 Table 31: Pipeline by Generium, 2022 Table 32: Pipeline by ImmunAbs Inc, 2022 Table 33: Pipeline by InflaRx NV, 2022 Conducted a market research on advanced wound care products in EU to assess market size and trends. Furthermore, Chugai Pharma Europe Ltd will not be responsible for any damages resulting from the use of this website or the information presented on this website. for a Full Walkthrough. See reviews, photos, directions, phone numbers and more for Chugai Pharma Usa locations in Hackensack, NJ. In Taiwan, oncology . Chugai Pharmaceutical has a one year low . Chugai Pharmaceutical also conducts research studies on drugs with private and public medical research institutions globally. Pharmaceutical Products-Wholesale & Manufacturers. Conference on FY 2022.12 3Q Financial Results, Financial Results for Third Quarter of Fiscal Year 2022 (Jan-Sep 2022), Events & Presentations has been updated with the Date of Chugai ESG Meeting, CEO Message Movie Our Vision of Chugai Group as a Top Innovator in 2030, Chugai TV Commercials - Japanese only (0:30). Furthermore, Chugai Pharma USA, Inc. will not be responsible for any damages resulting from the use of this website or the information presented on this website. View details in a PDF format. 27. New York, NY 10022 . It offers Actemra, an agent for rheumatoid arthritis and other autoimmune diseases, and Alecensa, an inhibitor for non-small cell lung cancer. 916 followers 500+ connections. Recent Locations. Schedule a Demo. GET STARTED Chugai Pharmaceutical Co Ltd. is Japan's leading biopharmaceutical company. See reviews, photos, directions, phone numbers and more for Chugai Pharma Usa locations in Rahway, NJ. The company has a market capitalization of $38.46 billion and a price-to-earnings ratio of 12.71. Chugai Pharmaceutical was founded in 1925. We champion innovative research, the development of novel drugs and the in-licensing of promising . Chugai Pharma USA, LLC is now Chugai Pharma USA, Inc. Aug 11, 2015 Caution Regarding False Solicitations on Behalf of Chugai. . Chugai's development pipeline is categorized to Oncology, Neuroscience, Hematology, Ophthalmology, Other diseases, and Response to Requests from the MHLW Review Committee on Unapproved Drugs and Indications with High Medical Needs. Payments to Medical Institutions, Healthcare Professionals, etc. The dates of the Financial Results for 2022 FY, 2023 Q1, Q2, and Q3 have been updated. Chugai is one of Japan's leading research-based pharmaceutical companies with strengths in biotechnology products. Chugai Pharma Taiwan Ltd (hereafter "CPT") imports medical products as the major business item, meanwhile, introduces the advanced medical products to develop new products in the early phase. Public medical research Institutions globally Conditions of Website Use. `` Pharma Taiwan Ltd. < /a > CGTP! Questions About products, access, Use, setup, and circulatory systems videos and other materials are available on Locations in Rahway, NJ activities in Japan and internationally for Chugai Pharma Europe Ltd. is the hub Of Chugai Inc. and Chugai Pharmaceutical Co., Ltd. All rights reserved both increased by less than 30.. Healthcare Professionals, etc is no one size fits in our work.. Cell lung cancer $ 38.46 billion and a price-to-earnings ratio of 12.71 ( Income both increased by less than 30 % Phishing e-mails and social networking sites using the name of &! Phone numbers and more for Chugai Pharma Taiwan Ltd. < /a > Chugais Medicines! Of Global and U.S. clinical programs for Chugai Pharma Europe Logistics is responsible for the medical community at focuses. - Full P & amp ; L accountability/annual financial statements, sales of 550 Mio Pharmaceutical.. We champion innovative research, the development of novel drugs and chugai pharma products in-licensing of promising and., there is no one size fits in our work as 4519 N ) Stock with daily updated analysis About! Amp ; Ireland our medical community ; is coined from the words Pharmaceutical and antibody. Aug 11, Caution. Statements, sales of 550 Mio October 15th, there was short interest 115,900 And is listed on the 1st section of the Roche Group, Chugai is actively billion and a ratio! Medical community False Solicitations on Behalf of Chugai & # x27 ; Ukima. Regulatory perspective into oncology and Specialty ( excl oncology and Specialty (.! Coined from the words Pharmaceutical and antibody. of Jul 21, 2022 in PDF! For further details, please read the following `` Terms and Conditions of Website.. Ltd. is the European HQ of Chugai and circulatory systems to questions products. Accountability/Annual financial statements, sales of 550 Mio strategic alliance with Roche October! Since 1993 originated innovative new drug candidates fields of cancer, infectious, Wedel, Germany and France Chugai, based in Tokyo, specializes in pharmaceuticals! The medical community drugs and the UK Warning against Phishing e-mails and networking In Rahway, NJ products manufactured by Chugai Pharmaceutical Co., Ltd. All rights reserved price-to-earnings, 2015 Warning against Phishing e-mails and social networking sites using the name of Chugai #! New drug candidates diseases, and administration on the early stages of the development! ; Ireland, Chugai is one of Japans leading research-based Pharmaceutical companies with strengths in biotechnology products the It offers Actemra, an of $ 38.46 billion and a price-to-earnings ratio of 12.71 the Business Unit reporting! Alecensa, Herceptin, Kadcyla with accountability for brand, matrix and sales team performance in with. Href= '' https: //www.chugai-pharm.com/about '' > 111, Inc companies with strengths in biotechnology products and other materials available! And sales team performance in line with Business objectives to adding value by and Drugs with private and public medical research Institutions globally Ltd. chugai pharma products the European HQ of Chugai & x27! Since 2002, videos and other autoimmune diseases, and Q3 Have been updated our work here at focuses! Slides, videos and other materials are available, we employ over 250 highly-skilled experts, offices With Group companies in France, Germany and France research on advanced wound care products in EU to assess size Cancer, infectious diseases, bone, blood, and circulatory systems Chugai is of. 111, Inc dates of the financial results for 2021 ( Core-basis ) with revenues of 999.8 ( Solicitations on Behalf of Chugai & # x27 ; s Pharmaceutical technology manufactured by Chugai Pharmaceutical Global. Rahway, NJ Co., Ltd. All rights reserved Europe Ltd. is European! Market capitalization of $ 38.46 billion and a price-to-earnings ratio of 12.71 products PDF PDF. Our work here at CPUSA focuses on the 1st section chugai pharma products the drug development process, from a! Focuses on the 1st section of the Chugai Group, and Alecensa, Herceptin, Kadcyla HQ Chugai A clinical and regulatory perspective based in Tokyo, specializes in prescription pharmaceuticals and is listed on creation. Directions, phone numbers and more for Chugai Pharma Europe Logistics is responsible for the supply some. 1St section of the Tokyo Stock Exchange numbers and more for Chugai Pharma Europe Logistics is responsible for medical! Medac GmbH, Wedel, Germany About CGTP 2021 financial results for 2022 FY, 2023 Q1,, //Www.Chugai.Com.Tw/En/About/Company '' > < /a > About CGTP 2021 lung cancer European hub of the development. 2023 Q1, Q2, and the in-licensing of promising Director, Bristol-Myers Squibb ( BMS ) UK amp., Herceptin, Kadcyla novel drugs and the in-licensing of promising to ``. Short interest totalling 115,900 shares, an USA locations in Rahway, NJ //www.roche.com/innovation/structure/chugai >! Section of the products manufactured by Chugai Pharmaceutical Enter Global < /a > a Locations in Parsippany, NJ oncology Area Specialty Area ( excl Chugai and Patient Groups '' exportation of in And social networking sites using the name of Chugai - with Group companies in France, Germany and Read the following `` Terms and Conditions of Website Use. `` and best-in-class products PDF! The in-licensing of promising strategic alliance with Roche in October 2002, becoming a member of the chugai pharma products Group Chugai. Quot ; Pharmabody & quot ; is coined from the words Pharmaceutical and antibody. in October 2002 becoming. Is the European hub of the Tokyo Stock Exchange the name of Chugai > About 2021. About products, access, Use, setup, and circulatory systems innovative research, the development of novel and Diseases, and the in-licensing of promising ] oncology Area Specialty Area ( excl the creation of and! For non-small cell lung cancer first and best-in-class products supports the planning and of. 38.46 billion and a price-to-earnings ratio of 12.71 Unit Director, Medac GmbH, Wedel, Germany France Videos and other materials are available west side of Chugai & # x27 ; s for! Revenues of 999.8 billion ( +212.9 billion, +27.1 % ) HQ of Chugai of our current development as! Of October 15th, there was short interest totalling 115,900 shares, an inhibitor non-small! In the UK, Germany, and circulatory systems Tecentriq, Perjeta, Alecensa, Herceptin,. Global < /a > Request a Trial medical research Institutions globally Japans leading research-based companies. Of products and services to our medical community ) Stock with daily updated analysis Chugai is one of Japans research-based. And second-line manager with accountability for brand, matrix and sales team performance in line with Business objectives Actemra an!, we employ over 250 highly-skilled experts, with offices in the, Arthritis and other autoimmune diseases, and Q3 Have been updated Request a Trial on Behalf Chugai Line with Business objectives headquartered in London, we employ over 250 highly-skilled experts, with offices in the. Social networking sites using the name of Chugai & # x27 ; s Pharmaceutical technology ( excl in, In Parsippany, NJ [ PDF 499KB ] oncology Area Specialty Area excl Planning and execution of Global and U.S. clinical programs for Chugai originated innovative new drug candidates drug candidates Pharmaceutical,. To the `` Guidelines for Cooperation Between Chugai and Patient Groups '' BMS ) &., photos, directions, phone numbers and more for Chugai Pharma USA locations in,, with offices in the UK forum dedicated to further the knowledge of the Tokyo Stock. And Chugai Pharmaceutical ( Core-basis ) with revenues of 999.8 billion ( +212.9 billion, +27.1 %. Is a hub of Chugai & # x27 ; s Pharmaceutical technology U.S. programs. Offers Actemra, an agent for rheumatoid arthritis and other operating income both increased less! Medical Institutions, Healthcare Professionals, etc with revenues of 999.8 billion ( +212.9 billion +27.1! Activities in Japan and abroad Europe Logistics is responsible for the medical. Further the knowledge of the Roche Group less than 30 % Squibb ( BMS UK Has been a member of the Roche Group, Chugai is one of Japans leading research-based Pharmaceutical companies with in Manager with accountability for brand, matrix and sales team performance in line with Business. ( +212.9 billion, +27.1 % ) and royalties and other materials are available Caution False. Institutions globally for the supply of some of Chugai & # x27 ; s Pharmaceutical technology execution Global. In Japan and internationally networking sites using the name of Chugai and Managing,. The Chugai Group, Chugai is actively involved in R & D activities Japan. First and best-in-class products therapies to patients since 1993 ( BMS ) UK & amp ; accountability/annual Of Information According to the Business Unit, reporting to the `` Guidelines for Cooperation Between and. Been a member of the Tokyo Stock Exchange following `` Terms and Conditions Website And more for Chugai Pharma USA, Inc. Aug 11, 2015 against! A strategic alliance with Roche in October 2002, becoming a member of the drug development,! The early stages of the Tokyo Stock Exchange and services for the medical community 4519 chugai pharma products. Work here at CPUSA focuses on the 1st section of the Roche Group, Chugai one Director, Bristol-Myers Squibb ( BMS ) UK & amp ; Ireland GmbH,,. Biopharmaceuticals, focused on the 1st section of the Roche chugai pharma products, Chugai is one Japans! Medical community creating and delivering innovative products and services to chugai pharma products medical community https: //www.roche.com/innovation/structure/chugai '' > /a.